News
Back to News

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

Dr. Richard Pazdur

Roger M. Perlmutter, MD, PhD

The FDA has expanded the approval for single-agent pembrolizumab (Keytruda) to include the frontline treatment of patients with advanced melanoma regardless of BRAF status, based on a substantial improvement in progression-free and overall survival compared with ipilimumab (Yervoy) in the phase III KEYNOTE-006 trial.1

In the KEYNOTE-006 study, which compared 2 pembrolizumab regimens with ipilimumab, the PD-L1 inhibitor reduced the risk of disease progression by >40% and the risk of death by >30%.

"As recently as five years ago, there were few treatment options for patients suffering from advanced melanoma," Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories, the developer of the PD-1 inhibitor, said in a statement. “Today’s news is another exciting milestone for Keytruda and for patients with this disease." Click here to read the full article at OncLive.com




Back to News


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28
Filter By